<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MILLIPRED- prednisolone tablet </strong><br>Zylera Pharmaceuticals, LLC<br></p></div>
<h1>
<span class="Bold">MILLIPRED™<br></span>(prednisolone tablets USP, 5 mg)<br><br><span class="Bold">MILLIPRED™DP - 6-Day TabletDose Pack<br></span>(prednisolone tablets USP, 5 mg)<br><br><span class="Bold">MILLIPRED™DP - 12-Day<br></span><span class="Bold">Tablet</span><span class="Bold"> Dose Pack<br></span>(prednisolone tablets USP, 5 mg)<br><br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_4cda54a9-61d5-4273-83ec-af1be2068144"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic,whichare readily absorbed from the gastrointestinal tract.Prednisolone is a white crystallinepowder,very slightly soluble in water.It isdesignated chemically as pregna-1,4-diene-3,20-ione,11,17,21-trihydroxy-,(11)-.The structural formula is represented below:</p>
<br><div class="Figure"><img alt="CHEMICAL FORMULA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=863ad743-eec0-46f0-beba-c1556384c636&amp;name=millipred-1.jpg"></div>
<p><span class="Bold">C<span class="Sub">21</span>H<span class="Sub">28</span>O<span class="Sub">5</span>        M.W.  360.45</span><br><br></p>
<p>Millipred and Millipred DP Tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, crospovidone, D&amp;C Yellow No.10,docusate sodium, FD&amp;CYellow No.6,magnesium stearate and sodium benzoate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fc0cd71b-23e0-4dc8-8749-6a9e7ad02f94"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Naturally occurring glucocorticoids (hydrocortisone and cortisone),which also have salt retaining properties, are used as replacement therapy in adrenocortical deficiency states. Prednisolone is primarily used for its potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_b792b911-c85e-4ec2-b70c-68780083f958"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First"><span class="Italics">1. </span><span class="Italics">Endocrinedisorders. </span>Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> Nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span> <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> associated with cancer</p>
<p><span class="Italics">2. </span><span class="Italics">Rheumatic disorders. </span>As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>; including juvenile heumatoid <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> (selected cases may require low-dose maintenance therapy)</li>
<li><span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></li>
<li>Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span></li>
<li>Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></li>
<li>Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></li>
<li>Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span></li>
</ul>
<p><span class="Italics">3. </span><span class="Italics">Collagen diseases. </span>During an exacerbation or as maintenance therapy in selected cases of:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span> Acuterheumatic carditis</li>
<li>Systemic <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span> (poly-my-ositis).</li>
</ul>
<p><span class="Italics">4. </span><span class="Italics">Dermatologic diseases</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span></li>
<li><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (Ste-vens-Johnson syndrome);</li>
<li><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span>.</li>
</ul>
<p><span class="Italics">5. </span><span class="Italics">Allergic </span><span class="Italics">states. </span>Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:</p>
<ul class="Disk">
<li>Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></li>
<li>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions</li>
</ul>
<p><span class="Italics">6. </span><span class="Italics">Ophthalmic diseases. </span>Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></li>
<li>Allergic corneal marginal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></li>
<li><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> ophthalmicus</li>
<li><span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span> and <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span></li>
<li>Anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></li>
<li>Diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis</li>
<li><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span></li>
<li>Sympathetic ophthalmia</li>
</ul>
<p><span class="Italics">7. </span><span class="Italics">Respiratory diseases</span></p>
<ul class="Disk">
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></li>
<li>Loeffler’s syndrome not manageable byother means</li>
<li>Berylliosis</li>
<li>Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous</li>
<li>chemotherapy</li>
<li><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span></li>
</ul>
<p><span class="Italics">8. </span><span class="Italics">Hematologic disorders</span></p>
<ul class="Disk">
<li>Idiopathic thrombocytopenic purpurain adults</li>
<li>Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults</li>
<li>Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></li>
<li>Erythroblastopenia (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>Congenital (erythroid) hypoplasticanemia</li>
</ul>
<p><span class="Italics">9. </span><span class="Italics">Neoplastic diseases. </span>For palliative management of:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults</li>
<li><span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span> of childhood</li>
</ul>
<p><span class="Italics">10. </span><span class="Italics">Edematous states. </span>To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathictype or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
<p><span class="Italics">11. </span><span class="Italics">Gastrointestinal diseases. </span>To tide the patient over a critical period of the disease in:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">Regional enteritis</span></li>
</ul>
<p><span class="Italics">12. </span><span class="Italics">Nervous system. </span>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.</p>
<p><span class="Italics">13. </span><span class="Italics">Miscellaneous</span></p>
<ul class="Disk">
<li>Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy</li>
<li>Trichinosis with neurologic or myocardial involvement</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a3f3db23-3e66-4bc1-88a0-11be99af6b14"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_fed99237-0410-4a1e-8e3f-8ad07ef642bd"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals.</p>
<p><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/ or prior corticosteroid treatment to the risk is also not known If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated.(See the respective package inserts for complete VZIG and IG prescribing information.) If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents may be considered.</p>
<p>In patients on corticosteroid therapy subjected to unusual stress increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungior viruses.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_d4b92863-37ab-45fd-8e0d-dd5637735e4b"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">Usage in Pregnancy</span></h1>
<p class="First">Since adequate human reproduction studies have not been done with corticosteroids, the  use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus.  Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>. Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are</p>
<p>less likely to occur with synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>While on corticosteroid therapy patients should not be vaccinated against <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.</p>
<p>The use of prednisolone in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur.</p>
<p>During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_60860918-8414-4270-bbc9-afd6e33f3e99"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<p class="First">PERSONS WHO ARE ON IMMUNOSUPPRESSANT DOSES OF CORTICOSTEROIDS SHOULD BE WARNED TO AVOID EXPOSURE TO <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">CHICKENPOX</span> OR <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">MEASLES</span>. PATIENTS SHOULD ALSO BE ADVISED THAT IF THEY ARE EXPOSED, MEDICAL ADVICE SHOULD BE SOUGHT WITHOUT DELAY.<br><br>DRUD-INDUCED <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">SECONDARY ADRENOCORTICAL INSUFFICIENCY</span> MAY BE MINIMIZED BY GRADUAL REDUCTION OF DOSAGE. THIS TYPE OF RELATIVE INSUFFICIENCY MAY PERSIST FOR MONTHS AFTER DISCONTINUATION OF THERAPY; THEREFORE, IN ANY SITUATION OF STRESS OSSURING DURING THAT PERIOD, HORMONE THERAPY SHOULD BE REINSTITUTED. SINCE MINERALO-CORTICOID SECRETION MAY BE IMPAIRED, SALT AND/OR A MINERALOCORTICOID SHOULD BE ADMINISTERED CONCURRENTLY. THERE IS AN ENHANCED EFFECT OF CORTICOSTEROIDS ON PATIENTS WITH <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">HYPOTHYROIDISM</span> AND IN THOSE WITH CIRRHOSIS. CORTICOSTEROIDS SHOULD BE USED CAUTIOUSLY IN PATIENTS WITH OCCULAR HERPES SIMPLEX BECAUSE OF POSSIBLE <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">CORNEAL PERFORATION</span>.<br><br>THE LOWEST POSSIBLE  DOSE OF CORTIOCSTEROIDS SHOULD BE USED TO CONTROL THE CONDITION UNDER TREATMENT, AND WHEN REDUCTION IN DOSE IS POSSIBLE, THE REDUCTION SHOULD BE GRADUAL. PSYCHIC DERANGEMENTS MAY APPEAR  WHEN CORTICOSTEROIDS ARE USED, RANGING FROM <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">EUPHORIA</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">INSOMNIA</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">MOOD SWINGS</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">PERSONALITY CHANGES</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> TO FRANK <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOTIC</span> MANIFESTATIONS. ALSO, EXISTING <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">EMOTIONAL INSTABILITY</span> OR <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOTIC</span> TENDENCIES MAY BE AGGRAVATED BY CORTICOSTEROIDS.<br><br>ASPIRIN SHOULD BE USED CAUTIOUSLY IN CONJUNCTION WITH CORTICOSTEROIDS IN HYPOTHROMBINEMIA.<br><br>STEROIDS SHOULD BE USED WITH CAUTION IN NONSPECIFIC <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ULCERATIVE COLITIS</span>, IF THERE IA S PROBABILITY OF IMPENDING PERFORATION, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">ABSCESS</span> OR OTHER PYOGENIC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">DIVERTICULITIS</span>; FRESH INTESTINAL ANASTOMOSES; ACTIVE OR LATENT <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">PEPTIC ULCER</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL INSUFFICIENCY</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span> AND <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span>.<br><br>GROWTH AND DEVELOPMENT OF INFANTS AND CHILDREN ON PROLONGED CORTICOSTEROID THERAPY SHOULD BE CAREFULLY OBSERVED.<br><br>ALTHOUGH CONTROLLED CLINICAL TRIALS HAVE SHOWN CORTICOSTEROIDS TO BE EFFECTIVE IN SPEEDING THE RESOLUTION OF ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">MULTIPLE SCLEROSIS</span> THEY DO NOT SHOW THAT THEY AFFECT THE ULTIMATE OUTCOME OR NATURAL HISTORY OF THE DISEASE. THE STUDIES DO SHOW THAT THE RELATIVELY HIGH DOSES OF CORTICOSTEROIDS ARE NECESSARY TO DEMONSTRATE A SIGNIFICANT EFFECT. (SEE DOSAGE AND ADMINISTRATION SECTION.)<br><br>SINCE COMPLICATIONS OF TREATMENT WITH GLUCOCORTICOIDS ARE DEPENDENT ON THE SIZE OF THE DOSE AND THE DURATION OF TREATMENT, A RISK/BENEFIT DECISION MUST BE MADE IN EACH INDIVIDUAL CASE AS TO DOSE AND DURATION OF TREATMENT AND AS TO WHETHER DAILY OR INTERMITTENT THERAPY SHOULD BE USED.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_2582aae8-d094-42b1-a0d4-c7ffbc1929ac"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay. Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage.</p>
<p>This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
<p>There is an enhanced effect of corticosteroids on patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; active or latent</p>
<p><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.</p>
<p>Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> they do not show that they affect the ultimate outcome or natural history of the dis-ease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.(See <span class="Bold"><span class="Bold"><a href="#LINK_c4dc1df7-c7b0-41e2-a59d-9386794cd3c6">DOSAGE AND ADMINISTRATION</a></span> </span>section.)</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_c892ce31-ebe0-426c-b0e0-bb1e4282f583"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First"><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span></li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients</li>
<li>Potassium loss</li>
<li><span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></li>
</ul>
<p><span class="Italics">Musculoskeletal</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">Steroid myopathy</span></li>
<li>Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span></li>
<li><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></li>
<li>Vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span></li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads</li>
<li>Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones.</li>
</ul>
<p><span class="Italics">Gastrointestinal</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></li>
<li>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span></li>
<li>Ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</li>
</ul>
<p><span class="Italics">Dermatologic</span></p>
<ul class="Disk">
<li>Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing</li>
<li>Thin fragile skin</li>
<li><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span></li>
<li>Facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></li>
<li>Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>May suppress reactions to skin tests.</li>
</ul>
<p><span class="Italics">Neurological</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (pseudotumorcerebri) usually after treatment</li>
<li><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
</ul>
<p><span class="Italics">Endocrine</span></p>
<ul class="Disk">
<li>Menstrual irregularities</li>
<li>Development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state</li>
<li>Suppression of growth in children</li>
<li>Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness</li>
<li>Decreased carbohydrate tolerance</li>
<li>Manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus</li>
<li>Increased requirements for insulin or oral hypoglycemic agents in diabetics</li>
</ul>
<p><span class="Italics">Ophthalmic</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span></li>
<li><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></li>
<li><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>.</li>
</ul>
<p><span class="Italics">Metabolic</span></p>
<ul class="Disk"><li>Negative nitrogen balance due to protein catabolism</li></ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_c4dc1df7-c7b0-41e2-a59d-9386794cd3c6"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">The initial dosage of Millipred and Millipred DP Tablets may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice, while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisolone should be discontinued and the patient transferred to other appropriate therapy.</p>
<p><span class="Bold">IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THERESPONSE OF THE PATIENT.</span></p>
<p>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary</p>
<ul class="Disk"><li>to increase the dosage of prednisolone for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</li></ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6ec75931-a573-4111-90cf-e101a9cbb84c"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">Alternate-Day Therapy</span></h2>
<p class="First">Alternate-Day Therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning. The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state, corticoid withdrawal symptoms, and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> in children.</p>
<p>The rationale for this treatment schedule is based on two major premises: (a)the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for reestablishment of more nearly normal hypothalamic- pituitary-adrenal (HPA)activity on the off-steroid day.</p>
<p>A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise from a low point about 10 p.m.to a peak level about 6 a.m.</p>
<p>Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 a.m. and 8 a.m. This rise in cortisol dampens ACTH production and in turn adrenocortical activity.There is a gradual <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in plasma corticoids during the day, the lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing’s disease, a syndrome of adrenocortical hyperfunction characterized by <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> with centripetal fat distribution, thinning of the skin with easy bruisability, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle wasting</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, etc. The same clinical findings of <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span> may be noted during the long-term pharmacologic dose corticoid therapy administered in conventional daily divided doses.  It would appear, then, that a disturbance in the diurnal cycle with maintenance of elevated corticoid values during the night may play a significant role in the development of undesirable corticoid effects.</p>
<p>Escape from these constantly elevated plasma levels for even short periods of time may be instrumental in protecting against undesirable pharmacologic effects.</p>
<p>During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment.</p>
<p>During this time the patient is vulnerable to any stressful situation.</p>
<p>Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenocortical suppression for two or more days. Other corticoids, including methylprednisolone,  hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenocortical suppression for 1 1/4 days to 1 1/2 days following a single dose) and thus are recommended for alternate day therapy.</p>
<p><span class="Italics">The following should be kept  in mind when considering alternate-day therapy:</span></p>
<ol class="Arabic">
<li>Basic principles and indications for corticosteroid therapy should apply. The benefits of alternate-day therapy should not encourage the indiscriminate use of steroids.</li>
<li>Alternate-day therapy is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.</li>
<li>In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with alternate-day therapy. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate-day therapy is intended.<br>Once control has been established, two courses are available:(a) change to alternate-day therapy and then gradually reduce the amount of corticoid given every other day, or (b) following control of the disease process, reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate-day schedule. Theoretically, course (a) may be preferable.</li>
<li>Because of the advantages of alternate-day therapy, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (e.g., patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>). Since these patients may already have a suppressed HPA axis, establishing them on alternate-day therapy may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.</li>
<li>As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for</li>
<li>Although many of the undesirable features of corticosteroid therapy can be minimized by alternate-day therapy, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient with whom corticoid therapy is being considered.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_c2bf1992-1149-4623-a2be-4b7f8b8d3577"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Millipred and Millipred DP Tablets (prednisolone tablets USP, 5 mg) are scored, round, peach tablet imprinted DAN DAN 5059 supplied in bottles of 100 (NDC 23594-505-01),a unit of use <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack of 21 tablets (NDC 23594-505-21) and a unit of use <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack of 48 tablets (NDC 23594-505-48) respectively.</p>
<p>Dispense in a well-closed container with child-resistant closure.</p>
<p>Store at 20°-25°C (68°-77°F).[See USP controlled room temperature.]</p>
<p>Manufactured By:<br>Watson Pharma Private Limited <br>Verna, Salcette Goa 403 722 <br>INDIA</p>
<p>Distributed By:<br>Zylera Pharmaceuticals <br>Research Triangle Park, <br>NC 27713</p>
<p>Revised:02/2014 <br>MILL021114</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_981ffdc8-d8e8-4ce6-bf9e-c287965f8efc"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">Principal Display Panel</span></h1>
<p class="First">NDC 23594-505-01<br>Millipred<br>Tablets<br>(prednisolone USP)<br>5 mg<br>Zylera<br>100 Tablets<br>Rx only</p>
<br><br><br><div class="Figure"><img alt="NDC 23594-505-01 Millipred Tablets (prednisolone USP) 5 mg Zylera 100 Tablets Rx only" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=863ad743-eec0-46f0-beba-c1556384c636&amp;name=millipred-2.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MILLIPRED 		
					</strong><br><span class="contentTableReg">prednisolone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23594-505</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREDNISOLONE</strong> (PREDNISOLONE) </td>
<td class="formItem">PREDNISOLONE</td>
<td class="formItem">5  mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (PEACH) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DANDAN5059</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23594-505-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:23594-505-21</td>
<td class="formItem">6  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:23594-505-48</td>
<td class="formItem">12  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080354</td>
<td class="formItem">03/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zylera Pharmaceuticals, LLC
							(032546121)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>88ed2e2b-47c4-4c44-b5d3-2ef6775a41c5</div>
<div>Set id: 863ad743-eec0-46f0-beba-c1556384c636</div>
<div>Version: 5</div>
<div>Effective Time: 20140311</div>
</div>
</div> <div class="DistributorName">Zylera Pharmaceuticals, LLC</div></p>
</body></html>
